Skip to main content

Table 1 Dose reduction (DR) steps per biologic

From: Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study—the BeNeBio study

Biologic

Normal dose

First step DR

Second step DR

Secukinumab

300 mg/4 weeks

300 mg/6 weeks

300 mg/8 weeks

Ixekizumab

80 mg/4 weeks

80 mg/6 weeks

80 mg/8 weeks

Brodalumab

210 mg/2 weeks

210 mg/3 weeks

210 mg/4 weeks

Guselkumab

100 mg/8 weeks

100 mg/12 weeks

100 mg/16 weeks

Risankizumab

150 mg/12 weeks

150 mg/18 weeks

150 mg/24 weeks

Tildrakizumab

100 or 200 mg/12 weeks

100 or 200 mg/18 weeks

100 or 200 mg/24 weeks

  1. Abbreviations: DR dose reduction, mg milligram
Back to article page

Trials

ISSN: 1745-6215